High Residual Platelet Reactivity After Clopidogrel. Extent of Coronary Atherosclerosis and Periprocedural Myocardial Infarction in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention

JACC: Cardiovascular Interventions

Volumn 3, Issue 1, 2010, Pages 35-40

  Mangiacapra, Fabio ^a,b   De Bruyne, Bernard ^a   Muller, Olivier ^a   Trana, Catalina ^a   Ntalianis, Argyrios ^a   Bartunek, Jozef ^a   Heyndrickx, Guy ^a   Di Sciascio, Germano ^b   Wijns, William ^a   Barbato, Emanuele ^a  

^a OLV HOSPITAL   (Belgium)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

atherosclerosis; clopidogrel; PCI; platelets

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

AGED; ANALYTICAL EQUIPMENT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS; STENT; THROMBOCYTE FUNCTION; THROMBOSIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 74049100575     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.10.024     Document Type: Article

References (24)

1. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
2. Davi G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
3. Keating F.K., Whitaker D.A., Kabbani S.S., Ricci M.A., Sobel B.E., and Schneider D.J. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 94 (2004) 725-728
4. Fitzgerald D.J., Roy L., Catella F., and FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med 315 (1986) 983-989
5. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
6. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., and Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52 (2008) 1128-1133
7. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
8. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to adenosine diphosphate detected by a point-of-care assay: a 12-month follow-up. Circulation 119 (2009) 237-242
9. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
10. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
11. Malinin A., Pokov A., Swaim L., Kotob M., and Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28 (2006) 315-322
12. van Werkum J.W., van der Stelt C.A., Seesing T.H., Hackeng C.M., and ten Berg J.M. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 4 (2006) 2516-2518
13. Yan B.P., Duffy S.J., Clark D.J., et al. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol 101 (2008) 1716-1722
14. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 50 (2007) 2173-2195
15. Gawaz M., Stellos K., and Langer H.F. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 6 (2008) 235-242
16. Furman M.I., Benoit S.E., Barnard M.R., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31 (1998) 352-358
17. Furman M.I., Barnard M.R., Krueger L.A., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1002-1006
18. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46 (2005) 1820-1826
19. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115 (2005) 101-108
20. Bates E.R. Ischemic complications after percutaneous transluminal coronary angioplasty. Am J Med 108 (2000) 309-316
21. Kereiakes D.J., Wang H., Popma J.J., et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 48 (2006) 21-31
22. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
23. Tcheng J.E., Lim I.H., Srinivasan S., et al. Stent parameters predict adverse clinical outcomes and response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circ Cardiovasc Intervent 2 (2009) 43-51
24. Cuisset T., Hamilos M., Sarma J., et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101 (2008) 1700-1703